 |
N-[(2S)-5-{[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino}-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide, bis-tosylate salt |
|---|---|
| Trade Name | |
| Orphan Indication | Myelofibrosis |
| USA Market Approval | USA |
| USA Designation Date | 2017-06-26 00:00:00 |
| Sponsor | Imago BioSciences, Inc.;2729 Debbie Court;San Carlos, California, 94070 |
Related Access Program